louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01811966: Preoperative Volume Substitution in Elective Surgery Patients
Official title: Preoperative Volume Substitution in Fasting Patients Undergoing Elective Surgery - Impact on Hemodynamic Stability During Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodynamic Instability
Hypovolemia
Anesthesia
Keywords: preoperative volume substitution
hypovolemia
preoperative fasting
Lead sponsor: Philipps University Marburg
Sponsor class: OTHER
First posted: 2013-03-15
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Preoperative fasting can evoke a hypovolemia which may cause a hemodynamic instability during introduction of anesthesia.

The purpose of this study is to test the hypothesis that a defined preoperative volume substitution compared to standard procedure will result in a reduced incidence of hemodynamic instabilities during introduction of anesthesia in elective surgery patients.

Detailed description: The preoperative fasting period often lasts longer than 2 hours as recommended by various national and international anesthetic guidelines. Thus, hypovolemia is more often then anticipated. In awake patients this condition is often masked. Introduction of anesthesia often leads to an unmasking of hypovolemia with a consecutive hemodynamic instability.

Aim of the study is to test the hypothesis that a preoperative volume substitution (8 ml/kg RingerAcetate Solution in 15 min. prior to introduction of anesthesia) reduces possible hemodynamic instabilities during initiation of anesthesia.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* thyreoid, parathyroid or gallbladder surgery
* general anesthesia

Exclusion Criteria:

* coronary artery disease
* congestive heart disease (≥ New York Heart Association (NYHA) 2)
* insulin dependent diabetes mellitus
* renal insufficiency (creatinine \> 2,0 mg/dl)
* cerebrovascular disease
* severe hypertension (≥ antihypertensive drugs)

Primary outcomes:
measure: hemodynamic instability
timeFrame: at time of introduction of anesthesia
Secondary outcomes:
measure: Stroke volume index > 35 ml/m2
timeFrame: at time of anesthesia
measure: Stroke volume variation < 12 %
timeFrame: at time of anesthesia
measure: Enddiastolic area (EDA) > 10 cm2
timeFrame: at time of anesthesia
measure: inferior vana cava diameter (VCI) > 15 mm
timeFrame: at time of anesthesia
Other outcomes:
Locations:
city: Marburg
country: Germany
facility: University Hospital of Marburg, Department of Anesthesia
Study officials:
affiliation: Department of Anesthesia and Intensive Care Medicine, University Hospital Marburg, Germany
name: Thomas Kratz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02741466: 18750-Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-04-18
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor (SPF) efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male or female
* Aged between 18-70 years old.
* Good health
* Signed and dated Informed Consent Form
* Signed and dated Health Insurance Portability and Accountability Authorization (HIPAA) Form
* An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* PRe-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose(MED)
timeFrame: Up to 15 minites
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minites
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01028066: Feeding Education in Patients Submitted to Coronary Angioplasty
Official title: Feeding Education in Patients Submitted to Percutaneous Transluminal Coronary Angioplasty: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Coronary Angioplasty
Coronary Disease
Keywords: nutritional intervention
nutritional counseling
feeding behavior
food consumption
angioplasty
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2009-12-09
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The simple knowledge that practices healthy lifestyle are important to reduce or prevent the progression of cardiovascular diseases it is not enough for effective changes accordingly. To nutritional education be successful, needs to promote changes in eating habits and not just transmit information. This is a behavioral intervention study in 200 consecutive patients submitted to percutaneous transluminary coronary angioplasty. The participants were randomized in two groups: intervention and control.

The intervention was a dialogic nutritional counseling and the control arm was a traditional nutritional counseling.

All participants will undergo long-term follow-up for cardiovascular events.

Detailed description: Patients were hospitalized to realize elective coronary angioplasty in a especialized hospital in cardiovascular disease.

All data were obtained by a trained nutritionist.

Eligibility criteria: Inclusion Criteria:

* preserved cognitive status

Exclusion Criteria:

* no availability to attend the meetings of nutritional guidance

Primary outcomes:
measure: Cardiovascular event (new ptca, cabg, ischemic acute syndrome, myocardial infarction) and mortality (all causes)
timeFrame: 1 year (all outcomes) and 3 years (all outcomes)
Secondary outcomes:
measure: - Evaluate changes in eating habits, according to the transtheoretical model to adopt healthy eating habits - Check change in food intake - Identify the nutritional status and cardiovascular risk
timeFrame: 1 year
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Heart Institute of Clinics Hospital of Medicine Faculty of São Paulo University
Study officials:
affiliation: Heart Institute HCFMUSP
name: Moacyr Roberto Cucê Nobre
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02993666: Comparison of Upper and Lower Body Air Warming in Patients Undergoing Thoracic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Core Body Temperature
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-12-15
Enrollment: 135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is conducted to evaluate the effectiveness of forced air warming using upper and lower body blankets by measuring core body temperature in patients undergoing video-assisted thoracic surgery in the lateral decubitus position over 2 hours of general anesthesia.


Eligibility criteria: Inclusion Criteria:

* patients undergoing video-assisted thoracic surgery over 2 hours
* ASA I, II and III
* age over 18 years

Exclusion Criteria:

* refuse to enroll
* patients with fever or hypothermia before surgery
* patients who required changes of position during surgery

Primary outcomes:
measure: intraoperative incidence of hypothermia
timeFrame: through surgery completion, up to 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: JH Seo
role: PRINCIPAL_INVESTIGATOR
References:
citation: Min SH, Yoon S, Yoon SH, Bahk JH, Seo JH. Randomised trial comparing forced-air warming to the upper or lower body to prevent hypothermia during thoracoscopic surgery in the lateral decubitus position. Br J Anaesth. 2018 Mar;120(3):555-562. doi: 10.1016/j.bja.2017.11.091. Epub 2017 Dec 5.
Clinical trial NCT01609166: Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
Official title: Placebo-controlled Trial to Determine the Effectiveness of a 3% Allopurinol-base Topical Agent for Prevention of Capecitabine-induced Hand-foot Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hand-foot Syndrome
Keywords: Hand-foot Syndrome
capecitabine
allopurinol
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
First posted: 2012-05-31
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial is conducted on the basis of preliminary data that a 3% allopurinol-based topical agent may prevent HFS.

A randomized, double-blind phase III trial will evaluate 40 patients receiving their first ever cycle of capecitabine at a dose of either 2,000 or 2,500 mg/m2 per day for 14 days. Patients will be randomly assigned to a 3% allopurinol versus a placebo cream, which will be applied to the hands and feet twice per day for 6 months after the start of capecitabine. Patients will be examined every month and the investigators will take some photographs of hands and feet. HFS toxicity grade (Common Terminology Criteria for Adverse Events \[CTCAE\]v3.0) will be also collected at baseline and at the end of each cycle. The primary end point is the incidence of moderate/severe HFS symptoms at the end of capecitabine treatment , based on the patient-reported dermatological exploration.


Eligibility criteria: Inclusion Criteria:

* Patients older than 18years-old,that initiate treatment with oral capecitabine, without signs of hand-feet syndrome toxicity.
* Free acceptance to participate part in this clinical trial, with signature of the form of informed assent approved for the study, writing of the volunteer.

Exclusion Criteria:

* Age lower than 18 years
* Precedents of allergy, idiosyncrasy or hypersensitivity to the medicament.
* Denial of the patient to sign the informed assent.
* Any disorder or current / previous treatment that, in the opinion of the investigator, incapacitates the patient to take part in the study.

Primary outcomes:
measure: Changes in the signs of hand-foot syndrome
timeFrame: At 1-2-3-4-5-6 months
Secondary outcomes:
measure: Changes in the symptoms of hand-foot syndrome
timeFrame: At 1-2-3-4-5-6 months
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
References:
Clinical trial NCT01597466: Epidrum for Thoracic Epidural Analgesia
Official title: A Comparison Study of Two Different Techniques for Identifying the Epidural Space in Patients Requiring Thoracic Epidural Analgesia: a Prospective Multicentric Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Lead sponsor: Hopital Foch
Sponsor class: OTHER
First posted: 2012-05-14
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the use of the Epidrum device to identify the epidural space in patients requiring thoracic epidural analgesia.


Eligibility criteria: Inclusion Criteria:

* Elective major thoracic surgery requiring thoracic epidural analgesia

Exclusion Criteria:

* Contraindication to epidural anesthesia
* Marked spinal deformities or a history of spinal instrumentation

Primary outcomes:
measure: Ease to identify the epidural space
timeFrame: 30 minutes
Secondary outcomes:
measure: Duration of epidural procedure
timeFrame: 30 minutes
measure: Number of cutaneous punctures
timeFrame: 30 minutes
measure: Number of needle redirections
timeFrame: 30 minutes
measure: Ease of epidural catheter insertion
timeFrame: 30 minutes
measure: Number of inadequate postoperative analgesia
timeFrame: one day after anesthesia
Other outcomes:
Locations:
city: Marseille
country: France
facility: CHU Marseille
city: Suresnes
country: France
facility: Hopital Foch
Study officials:
affiliation: Hopital Foch
name: Morgan Le Guen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hopital Foch
name: Marc Fischler, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02961166: Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients
Official title: Intravenous Immunoglobulin Therapy in ARDS Patients With Extracorporeal Membrane Oxygenation (ECMO) Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Distress Syndrome, Adult
Septic Shock
Keywords: IVIG
ARDS
ECMO
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: Universität Tübingen
First posted: 2016-11-10
Enrollment: 57
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ARDS patients treated by ECMO in the anesthesiological ICU of University Hospital Tuebingen between january 2012 and december 2015

Brief summary: 57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.

These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

Detailed description: 57 patients with ARDS requiring ECMO therapy were analyzed retrospectively. 28 patients had received IgM-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.

Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients.

These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.

Eligibility criteria: Inclusion Criteria:

* All data available
* ARDS with ECMO therapy

Exclusion Criteria:

* Data missing

Primary outcomes:
measure: Mortality
timeFrame: during ICU treatment, up to 28 days
Secondary outcomes:
measure: lengh of stay (LOS ICU)
timeFrame: up to 60 days
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
Study officials:
affiliation: University Hospital Tuebingen
name: Helene A Haeberle, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Prohaska S, Schirner A, Bashota A, Korner A, Blumenstock G, Haeberle HA. Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy. J Intensive Care. 2018 Feb 26;6:11. doi: 10.1186/s40560-018-0278-8. eCollection 2018.
Clinical trial NCT00851266: A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
Official title: A Dose-Escalation, Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of a Bivalent Influenza Peptide Conjugate Vaccine Formulated With Aluminum- and ISCOMATRIX(TM) Containing Adjuvants (BIPCV/IMX) Evaluated in Healthy Adults 18 to 35 Years of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Influenza
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-02-25
Enrollment: 187
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based adjuvant.


Eligibility criteria: Inclusion Criteria:

* Subject is in good physical health
* Subject is not in the category of individuals recommended by the CDC to receive influenza vaccine for the upcoming 2 influenza seasons
* Subject agrees not to seek vaccination with licensed influenza vaccines during the study
* Female subjects agree to use acceptable birth control for 6 weeks prior to first dose of vaccine until 1 month post Dose 3

Exclusion Criteria:

* Subject has a history of allergic reaction to the vaccine components
* Subject has has a fever within 3 days of screening
* Subject had a vaccination with an inactive virus within 14 days of Dose 1
* Subject had a vaccination with a live virus within 30 days of Dose 1

Primary outcomes:
measure: Safety: Safety and tolerability of BIPCV/IMX as assessed by vaccine-related SAEs; Immunogenicity: 1) A/M2 specific immunogenicity; 2) B/HA0 specific immunogenicity
timeFrame: Safety: 7 months; Immunogenicity: 1) 7 months; 2) 7 months
Secondary outcomes:
measure: Persistence of A/M2 and B/HA0 immunogenicity
timeFrame: Months 12, 18, and 24
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06954766: Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981
Official title: A Randomized, Double-blind, Sham-controlled, Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981 in Patients With Degenerative Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Knee Osteoarthritis
Keywords: CKD-981
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2025-05-02
Enrollment: 100
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to prove that the temporary symptom improvement effect on knee osteoarthritis using CKD-981

Detailed description: The aim of this pilot study is to evaluate the efficacy and safety of CKD-981 in patients with mild to moderate degenerative knee osteoarthritis who have been experiencing pain more than 8 weeks

Eligibility criteria: Inclusion Criteria:

* Patients between 40 years and 80 years old
* Patients who have experiencing knee pain more than 8 weeks
* VAS more than 40 mm
* Kellgren and Lawrence grade 2 and 3 in X' ray knee joint

Exclusion Criteria:

* Previous knee surgery in affected side
* Patients with Rheumatoid arthritis, connective tissue disease, Paget's disease
* Infection of knee joint
* BMI more than 35kg/m2

Primary outcomes:
measure: Change in weight-bearing knee pain measured using the Visual Analog Scale(VAS)
timeFrame: 6 Weeks
Secondary outcomes:
measure: Change in weight-bearing knee pain measured using the Visual Analog Scale(VAS)
timeFrame: 2 weeks, 4 weeks
measure: Change in total K-WOMAC (Korean Western Ontario and McMaster Universities Osteoarthritis Index) score from baseline
timeFrame: 2 weeks, 4 weeks, 6 weeks
Other outcomes:
Locations:
city: Wonju
country: Korea, Republic of
facility: Wonju Severance Christian Hospital
Study officials:
References:
Clinical trial NCT00913666: Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Official title: A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2009-06-04
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.


Eligibility criteria: Inclusion Criteria:

Healthy Control Subjects (Group 1)

* Must be in general good health.
* Must not have received interferons in the past.

All MS Subjects

* Clinical or laboratory-supported diagnosis of relapsing remitting MS (McDonald et al, criteria numbers 1-4).
* Either on AVONEX® or treatment-naïve.
* Have an EDSS score between 0.0 and 5.5, inclusive.

Exclusion Criteria:

* History of severe allergic or anaphylactic reaction or hypersensitivity to human albumin, to any interferon, to other components of the drug formulation.
* History of intolerance to acetaminophen, ibuprofen, naproxen, and aspirin that would preclude the use of at least one of these during the study.
* History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease.
* History of malignancy.
* The presence of any significant medical condition or psychiatric illness not due to MS that, in the investigator's opinion, would interfere with therapy
* History of uncontrolled seizures within the 3 months prior to enrollment.
* History of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment.
* Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 8 weeks prior to enrollment.
* Positive for human immunodeficiency virus (HIV), hepatitis C antibody (HCV) or positive for hepatitis B surface antigen (HbsAg) at screening.

Other inclusion and exclusion criteria apply as per protocol

Primary outcomes:
measure: Changes in bioanalytical measures after receiving therapy for 3 to 6 months
timeFrame: Study duration is 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Biogen
name: Biogen-Idec Investigator
role: PRINCIPAL_INVESTIGATOR
References: